Search results
Results from the WOW.Com Content Network
Lupron injection was approved by the FDA for treatment of advanced prostate cancer on 9 April 1985. [45] [4] [43] [44] Lupron depot for monthly intramuscular injection was approved by the FDA for palliative treatment of advanced prostate cancer on 26 January 1989. [8]
The average return to fertility is 9 to 10 months after the last injection, taking longer for overweight or obese women. By 18 months after the last injection, fertility is the same as that in former users of other contraceptive methods.
A gonadotropin-releasing hormone agonist (GnRH agonist) is a type of medication which affects gonadotropins and sex hormones. [1] They are used for a variety of indications including in fertility medicine and to lower sex hormone levels in the treatment of hormone-sensitive cancers such as prostate cancer and breast cancer, certain gynecological disorders like heavy periods and endometriosis ...
Progesterone (P4), sold under the brand name Prometrium among others, is a medication and naturally occurring steroid hormone. [20] It is a progestogen and is used in combination with estrogens mainly in hormone therapy for menopausal symptoms and low sex hormone levels in women.
Prescription drug list prices in the United States continually are among the highest in the world. [1] [2] The high cost of prescription drugs became a major topic of discussion in the 21st century, leading up to the American health care reform debate of 2009, and received renewed attention in 2015.
Now, approved for weight loss under the name Zepbound, the drug is available in six doses—2.5, 5, 7.5, 10, 12.5, and 15 milligrams, according to Eli Lilly, which makes the injectable medication ...
A depot injection, also known as a long-acting injectable (LAI), is a term for an injection formulation of a medication which releases slowly over time to permit less frequent administration of a medication.
Premenopausal women using depot injectable medroxyprogesterone acetate, a progestin related to CPA, as a form of progestogen-only birth control, have been observed to have a 2.2- to 3.6-fold increased risk of VTE. [171] [172] However, this could have reflected preferential prescription of DMPA to women considered to be at an increased risk of ...